Brief: Resverlogix announces third positive recommendation from data safety monitoring board for Apabetalone
17/03/2017 11:00
March 17 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces third positive recommendation from
data safety monitoring board for phase 3 study of Apabetalone
and provides an update on corporate activities
* DSMB will conduct additional periodic reviews and will
also perform a futility assessment once 125 adjudicated mace
have been observed
Source text for Eikon: ID:nPn42ybTca
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment